Aju Mathew, MD, MPhil

It is quite obvious that bone morbidity has a negative impact on our patients with breast cancer. The use of bone-modifying agents in this setting can yield significant quality-of-life benefits.

We know that bisphosphonates prevent or delay skeletal-related events in breast cancer metastatic to bone, prevent or treat bone loss in patients receiving adjuvant aromatase inhibitor therapy, and decrease bone recurrences and breast cancer–related deaths when used in the adjuvant setting in postmenopausal women with early-stage breast cancer.